Evidence map›Paper›PMID 22383880›Full record

ArticlePLoS pathogens2012

The Legionella pneumophila effector VipA is an actin nucleator that alters host cell organelle trafficking.

Irina Saraiva Franco, Nadim Shohdy, Howard A Shuman

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 82 citations in OpenAlex.

  1. Life science alliance · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cryo-EM structure revealed a novel F-actin binding motif in abioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. mLife · 2025
    Article
  9. Review
  10. Journal of bacteriology · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Eat or Be Eaten: Strategies Used byInfection and immunity · 2023
    Review
  15. Membrane-dependent actin polymerization mediated by thebioRxiv : the preprint server for biology · 2023
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Irina Saraiva FrancoDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, USA. irinafranco@hotmail.com
Nadim Shohdy
Howard A Shuman
University of Chicago · USColumbia University Irving Medical Center · US

Funding

GENETICS OF MONOCYTE KILLING BY BACTERIAR01AI023549 · NIAID · UNIVERSITY OF CHICAGO · PI SHUMAN, HOWARD A · 1986 to 2013
$6.8M
NIAID NIH HHS AI023549NIAID NIH HHS R01 AI023549
6 · The paper itself

Abstract

Legionella pneumophila, the causative agent of Legionnaires' disease, invades and replicates within macrophages and protozoan cells inside a vacuole. The type IVB Icm/Dot secretion system is necessary for the translocation of effector proteins that modulate vesicle trafficking pathways in the host cell, thus avoiding phagosome-lysosome fusion. The Legionella VipA effector was previously identified by its ability to interfere with organelle trafficking in the Multivesicular Body (MVB) pathway when ectopically expressed in yeast. In this study, we show that VipA binds actin in vitro and directly polymerizes microfilaments without the requirement of additional proteins, displaying properties distinct from other bacterial actin nucleators. Microscopy studies revealed that fluorescently tagged VipA variants localize to puncta in eukaryotic cells. In yeast these puncta are associated with actin-rich regions and components of the Multivesicular Body pathway such as endosomes and the MVB-associated protein Bro1. During macrophage infection, native translocated VipA associated with actin patches and early endosomes. When ectopically expressed in mammalian cells, VipA-GFP displayed a similar distribution ruling out the requirement of additional effectors for binding to its eukaryotic targets. Interestingly, a mutant form of VipA, VipA-1, that does not interfere with organelle trafficking is also defective in actin binding as well as association with early endosomes and shows a homogeneous cytosolic localization. These results show that the ability of VipA to bind actin is related to its association with a specific subcellular location as well as its role in modulating organelle trafficking pathways. VipA constitutes a novel type of actin nucleator that may contribute to the intracellular lifestyle of Legionella by altering cytoskeleton dynamics to target host cell pathways.

Indexed as

Host-Pathogen InteractionsLegionella pneumophilaActin CytoskeletonAnimalsBacterial ProteinsBiological TransportCHO CellsCricetinaeCricetulusHumansMutagenesisOrganellesOrganisms, Genetically ModifiedSaccharomyces cerevisiaeU937 CellsBacterial Proteins

Identifiers

PMID22383880
PMCPMC3285593
OpenAlexW1988062115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.